These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12130919)

  • 1. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.
    Dranitsaris G; Cottrell W; Evans WK
    Curr Opin Oncol; 2002 Jul; 14(4):375-83. PubMed ID: 12130919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
    Chisaki Y; Nakamura N; Yano Y
    Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ; Brandt A
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
    Evans WK; Le Chevalier T
    Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
    Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
    Novello S; Kielhorn A; Stynes G; Selvaggi G; De Marinis F; Maestri A; Foggi P; Tilden D; Tonato M; Crinò L; Rinaldi M; Migliorino AM; Scagliotti GV;
    Lung Cancer; 2005 Jun; 48(3):379-87. PubMed ID: 15893007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
    Shepherd FA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):3-11. PubMed ID: 10201515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?
    Scagliotti GV
    Nat Clin Pract Oncol; 2005 Apr; 2(4):190-1. PubMed ID: 16264931
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
    Maniadakis N; Fragoulakis V; Pallis AG; Simou E; Georgoulias V
    Ann Oncol; 2010 Jul; 21(7):1462-1467. PubMed ID: 20019086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.